Oncolytics Biotech (ONCY)
(Delayed Data from NSDQ)
$1.09 USD
+0.01 (0.93%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $1.08 -0.01 (-0.92%) 7:58 PM ET
2-Buy of 5 2
D Value D Growth F Momentum F VGM
Income Statements
Fiscal Year end for Oncolytics Biotech Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 25 | 21 | 21 | 19 | 16 |
Income After Depreciation & Amortization | -25 | -21 | -21 | -19 | -16 |
Non-Operating Income | 5 | 2 | 0 | 2 | -9 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -20 | -19 | -21 | -17 | -25 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -21 | -19 | -21 | -17 | -25 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -21 | -19 | -21 | -17 | -25 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -25 | -20 | -21 | -19 | -15 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -25 | -21 | -21 | -19 | -16 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 67.62 | 58.03 | 53.51 | 40.34 | 22.14 |
Diluted EPS Before Non-Recurring Items | -0.30 | -0.33 | -0.39 | -0.53 | -0.70 |
Diluted Net EPS (GAAP) | -0.30 | -0.33 | -0.39 | -0.42 | -1.13 |
Fiscal Year end for Oncolytics Biotech Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 6.50 | 8.23 | 5.32 | 4.98 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -6.50 | -8.23 | -5.32 | -4.98 |
Non-Operating Income | NA | 3.66 | 0.84 | -0.17 | 0.22 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | -2.84 | -7.39 | -5.50 | -4.76 |
Income Taxes | NA | 0.03 | 0.01 | 0.03 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -2.87 | -7.40 | -5.53 | -4.76 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -2.87 | -7.40 | -5.53 | -4.76 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 78.00 | 69.80 | 64.47 | 62.35 |
Diluted EPS Before Non-Recurring Items | NA | -0.04 | -0.10 | -0.09 | -0.07 |
Diluted Net EPS (GAAP) | NA | -0.03 | -0.11 | -0.09 | -0.08 |